Title: Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
Citation: J Manag Care Spec Pharm
2023;29:791–806.
Country: USA | Indication: COPD
This is a pharma-supported study
Scan to access the publication or visit
http://tago.ca/37133429
http://tago.ca/37133429